About this trial
The purpose of this clinical study is to evaluate the clinical and radiographic efficacy of Theravex Tissue Care Plus (Bone Bioactive Liquid) as an adjunct to a xenograft in crestal maxillary sinus elevation with simultaneous implant placement using the osseodensification technique. The study will enroll 16 partially edentulous patients who have inadequate posterior maxillary bone height. Participants will randomly undergo the sinus elevation and implant placement utilizing either a xenograft alone or a mixture of the xenograft and Theravex. The main question the study aims to answer is whether the adjunctive use of Theravex with a xenograft enhances vertical bone gain, bone density, and implant stability compared to using a xenograft alone.
Eligibility criteria
Qualifiers
Patient partially edentulous with maxillary posterior edentulous ridge after extraction of more than 4 months.
Both genders will be selected males and females.
Adult patients aged between 21 and 50 years of age.
Good general health (American Society of Anesthesiology Physical Status I-II).
Disqualifiers
Smokers
Pregnant and lactating females.
Poor oral hygiene (Full-Mouth Plaque Score (FMPS) > 20%).
Patients with occlusal or malalignment problems.
Trial design
Treatments tested in this trial
- Internal Sinus lifting using Theravex-Xenpgraft mixture
- Internal Sinus lifting using Xenpgraft alone